Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$18.31 -2.9%	$15.87	$9.57 ▼ $30.41	$2.53B	0.93	1.57 million shs	1.45 million shs
GMTX Gemini Therapeutics	$56.91 -1.9%	$49.90	$1.16 ▼ $14.10	$2.47B	-0.12	189,291 shs	275,330 shs
IBRX ImmunityBio	$2.81 -2.1%	$2.71	$1.83 ▼ $7.48	$2.48B	0.08	6.29 million shs	6.02 million shs
PHAT Phathom Pharmaceuticals	$9.18 -5.3%	$6.79	$2.21 ▼ $19.71	$640.89M	0.45	1.55 million shs	768,804 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	0.00%	+9.12%	+12.89%	+55.30%	-31.73%
GMTX Gemini Therapeutics	-1.88%	+3.95%	+11.90%	+46.94%	+21.16%
IBRX ImmunityBio	0.00%	+4.07%	-11.91%	+6.84%	-57.29%
PHAT Phathom Pharmaceuticals	0.00%	+4.73%	-8.47%	+88.11%	-12.15%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.5827 of 5 stars	3.4	2.0	0.0	3.4	2.1	1.7	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	2.3679 of 5 stars	3.6	1.0	0.0	0.0	3.0	1.7	0.6
PHAT Phathom Pharmaceuticals	4.2189 of 5 stars	4.5	4.0	0.0	0.0	1.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	138.75% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IBRX ImmunityBio	3.20	Buy	$12.25	335.94% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	90.63% Upside

Current Analyst Ratings Breakdown

Latest PHAT, IBRX, GMTX, and ARWR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00

(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	712.28	N/A	N/A	$1.54 per share	11.89
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IBRX ImmunityBio	$14.74M	168.26	N/A	N/A	($0.57) per share	-4.93
PHAT Phathom Pharmaceuticals	$81.86M	7.83	N/A	N/A	($3.71) per share	-2.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	21.53	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$334.33M	-$5.24	N/A	N/A	N/A	-422.42%	N/A	-90.11%	8/6/2025 (Estimated)

Latest PHAT, IBRX, GMTX, and ARWR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
GMTX Gemini Therapeutics	N/A	71.49	71.49
IBRX ImmunityBio	N/A	2.22	2.05
PHAT Phathom Pharmaceuticals	N/A	3.58	3.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
GMTX Gemini Therapeutics	75.42%
IBRX ImmunityBio	8.58%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
GMTX Gemini Therapeutics	12.90%
IBRX ImmunityBio	76.79%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	53.76 million	Optionable

PHAT, IBRX, GMTX, and ARWR Headlines

Recent News About These Companies

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Average Recommendation of "Buy" from Brokerages

July 13 at 6:05 AM | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.4% - Here's What Happened

July 7, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 7.4% - Here's Why

July 1, 2025 | marketbeat.com

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

June 25, 2025 | seekingalpha.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - Morningstar

June 24, 2025 | morningstar.comM

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

June 23, 2025 | news.bloomberglaw.comN

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading Down 6.8% - Time to Sell?

June 23, 2025 | marketbeat.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23, 2025 | globenewswire.com

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Average Rating of "Buy" by Brokerages

June 18, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?

June 16, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16, 2025 | globenewswire.com

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

June 10, 2025 | seekingalpha.com

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long

June 9, 2025 | seekingalpha.com

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

June 9, 2025 | zacks.com

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

June 8, 2025 | finanznachrichten.de

Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock

June 7, 2025 | investing.com

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

June 6, 2025 | msn.com

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

June 6, 2025 | uk.finance.yahoo.com

Phathom surges 125% after FDA grants petition on Voquezna exclusivity

June 6, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAT, IBRX, GMTX, and ARWR Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$18.31 -0.55 (-2.92%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$18.27 -0.04 (-0.22%)

As of 07/11/2025 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Gemini Therapeutics NASDAQ:GMTX

$56.91 -1.09 (-1.88%)

As of 07/11/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$2.81 -0.06 (-2.09%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$2.82 +0.02 (+0.53%)

As of 07/11/2025 07:55 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Phathom Pharmaceuticals NASDAQ:PHAT

$9.18 -0.51 (-5.26%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$9.34 +0.16 (+1.69%)

As of 07/11/2025 05:39 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time